Clinical Research into Central Nervous System Inflammatory Demyelinating Diseases Related to COVID-19 Vaccines.

Publication date: Mar 20, 2024

Various vaccines have been developed in response to the SARS-CoV-2 pandemic, and the safety of vaccines has become an important issue. COVID-19 vaccine-related central nervous system inflammatory demyelinating diseases (CNS IDDs) have been reported recently. We present one case of AstraZeneca vaccine-related myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease and a literature review of another 78 patients published from January 2020 to October 2022. Patients were divided into three vaccine types (viral vector, mRNA, and inactivated vaccines) for further analyses. Among 79 patients with COVID-19 vaccine-related CNS IDDs, 49 (62%) cases received viral vector vaccines, 20 (25. 3%) received mRNA vaccines, and 10 (12. 7%) received inactivated vaccines. Twenty-seven cases (34. 2%) were confirmed with autoantibodies, including fifteen patients (19%) with anti-MOG, eleven (13. 9%) with anti-aquaporin 4 (AQP4), and one (1. 3%) with both antibodies. Significantly, more males developed CNS IDDs post viral vector vaccines compared to mRNA and inactivated vaccines. Patients receiving mRNA vaccines were older than those receiving other types. Furthermore, mRNA and inactivated vaccines correlated more with anti-AQP4 antibodies, while viral vector vaccines showed higher MOG positivity. This research suggests potential associations between COVID-19 vaccine-related CNS IDDs and gender, age, and autoantibodies, contingent on vaccine types. Protein sequence analysis implies similarities between the S protein and AQP4/MOG. Further studies may elucidate the mechanisms of CNS IDDs, aiding vaccine selection for specific types.

Open Access PDF

Concepts Keywords
Aquaporin acute disseminated encephalomyelitis
Astrazeneca COVID-19 vaccines
Males transverse myelitis
October
Vaccines

Semantics

Type Source Name
disease MESH Demyelinating Diseases
disease MESH COVID-19
disease VO COVID-19 vaccine
disease VO vaccine
disease VO Glycoprotein
disease MESH associated disease
disease MESH Epilepsy
drug DRUGBANK Coenzyme M
disease MESH acute disseminated encephalomyelitis
disease MESH neuromyelitis optica spectrum disorders
disease MESH transverse myelitis
disease MESH multiple sclerosis
disease MESH optic neuritis
disease MESH men 3
disease IDO symptom
disease MESH infectious disease
pathway REACTOME Infectious disease
disease MESH infections
disease IDO infection

Original Article

(Visited 1 times, 1 visits today)